CVS treatment program discriminates against people with HIV, judge says
https://seekingalpha.com/news/4091709-cvs-must-face-hiv-patients-discrimination-suit?source=feed_sector_healthcare
Apr 20, 2024 - CVS Health (CVS) loses bid to avoid claims of discrimination against people with HIV. Read more here.
0
CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
https://www.zacks.com/stock/news/2258769/cvs-health-cvs-ascends-while-market-falls-some-facts-to-note?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2258769
Apr 19, 2024 - In the most recent trading session, CVS Health (CVS) closed at $69.75, indicating a +0.52% shift from the previous trading day.
0
CVS Health (CVS) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2258053/cvs-health-cvs-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2258053
Apr 18, 2024 - CVS Health (CVS) closed at $69.39 in the latest trading session, marking a +1.15% move from the prior day.
0
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
https://seekingalpha.com/news/4090466-cvs-favors-humira-copycats-hurting-abbvies-market?source=feed_sector_healthcare
Apr 17, 2024 - CVS Health's (CVS)decision to drop coverage for Humira and favor its cheaper biosimilars is hurting AbbVie's (ABBV) market dominance. Read more here.
0
Pages: 1
Page 1